Statement Of Cash Flows [Abstract]

Xbrane Biopharma - Filing #679209

Concept 2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Cash flows from (used in) operations before changes in working capital
287 522 SEK
163 186 SEK
Adjustments for decrease (increase) in trade and other receivables
85 132 SEK
1 699 SEK
Adjustments for increase (decrease) in trade and other payables
22 572 SEK
17 829 SEK
Cash flows from (used in) financing activities [abstract]
Payments for share issue costs
962,000 SEK
13 350 SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.